Nu Skin (NUS, $38.60) lowers earnings and sales outlook following China's scrutiny program on health products
Nu Skin Enterprises shares fell as much as -20% on Wednesday, after the company expressed concerns over headwinds from China’s increased scrutiny on health products.
The company, which develops and sells personal care products, revealed that it is adjusting its guidance for the year, mainly due to a dampened revenue outlook in Mainland China following the government’s 100-day campaign to review and scrutinize the health products and direct selling industries.
The increased scrutiny on the direct selling industry has reportedly led to a tightening of regulations on sales meetings - something that could adversely affect customer sentiment, as hinted by NU Skin CEO Ritch Wood. China accounted for 33% of Nu Skin’s revenue in 2018.
The company is scheduled to release its second quarter earnings reports on August 6. But as of now, Nu Skin is expecting its second-quarter earnings to range between 82 and 84 cents per share – down from its prior forecast of 91 to 98 cents per share. It now expects revenue between $622 million and $623 million, compared to its previous expectation of $660 million to $680 million.
Nu Skin has also lowered its full-year guidance. It now forecasts an earnings per share range of $3.20 to $3.35, compared to prior estimate of $3.80 to $4.05 a share. Its full year revenue expectation now sits between $2.48 billion to $2.52 billion, which is a range lower than its previous prediction of $2.76 billion to $2.81 billion.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NUS in downward trend: 10-day moving average broke below 50-day moving average on August 11, 2026
The 10-day moving average for NUS crossed bearishly below the 50-day moving average on August 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NUS as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NUS turned negative on August 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .
NUS moved below its 50-day moving average on August 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NUS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NUS advanced for three days, in of 269 cases, the price rose further within the following month. The odds of a continued upward trend are .
NUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.425) is normal, around the industry mean (23.642). P/E Ratio (4.769) is within average values for comparable stocks, (56.718). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.919). Dividend Yield (0.051) settles around the average of (0.034) among similar stocks. P/S Ratio (0.171) is also within normal values, averaging (2.707).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of personal care products and nutritional supplements
Industry HouseholdPersonalCare
Advertisement